PSA doubling time is the estimated time it takes a rising PSA level to double. It is usually reported in months and is used mainly after prostate cancer has been diagnosed or treated. A shorter doubling time means PSA is increasing more rapidly and is generally associated with a greater risk of cancer progression than a longer doubling time. It does not show where cancer is located, and it cannot diagnose recurrence by itself.
01. What Is PSA Doubling Time and How Is It Calculated?
What does PSA doubling time actually measure?
PSA doubling time measures the estimated time required for an increasing PSA concentration to become twice as high if the observed exponential rate of increase continues.
That is different from PSA velocity.
PSA velocity measures the absolute increase in ng/mL per year.
PSA doubling time measures the relative exponential rate of growth and reports how long a doubling would take.
| Measurement | What it asks | Typical unit |
|---|---|---|
| PSA velocity | How many ng/mL is PSA changing per year? | ng/mL/year |
| PSA doubling time | How long would the rising PSA take to double? | Months or years |
What is the PSA doubling-time formula?
Clinical PSA doubling time is normally calculated by fitting the natural logarithm of several PSA measurements against time.
The logarithmic calculation matters because doubling represents exponential rather than simple linear growth.
For an educational two-point example, if PSA doubles from 0.2 to 0.4 ng/mL over six months, the observed doubling time is approximately six months.
But modern clinical calculation should not normally depend on only two isolated PSA values.
How many PSA measurements are needed?
Current EAU guidance recommends using at least three PSA measurements when calculating PSA doubling time.
The guideline also suggests:
- a minimum interval of about four weeks between measurements when possible;
- using PSA values from no more than approximately the previous 12 months when the goal is to reflect current disease activity;
- and expressing the result in months, or sometimes weeks in very rapidly progressing disease.
Values taken too close together can magnify laboratory and biological variation.
What if PSA is falling instead of rising?
A true doubling time applies to an increasing PSA.
If PSA is stable or falling, the mathematical slope may produce an extremely long, negative or otherwise clinically unhelpful doubling-time value.
In that situation, reporting that PSA is stable or declining is usually clearer than trying to interpret a negative “doubling time.”
02. What Does a Short or Long PSA Doubling Time Mean?
What does a short PSA doubling time mean?
A short PSA doubling time means the PSA concentration is rising rapidly.
In men with known prostate cancer—particularly after local treatment—faster PSA doubling has repeatedly been associated with greater risks of:
- metastatic progression;
- prostate-cancer-specific mortality;
- and poorer outcomes after some salvage treatments.
The exact importance depends heavily on the clinical setting.
A six-month PSADT after biochemical recurrence following prostatectomy is not interpreted in exactly the same way as a six-month PSADT during active surveillance or non-metastatic castration-resistant prostate cancer.
What does a long PSA doubling time mean?
A longer PSADT means PSA is rising more slowly.
That is generally associated with a more indolent PSA-only recurrence than a very short doubling time.
Some men with biochemical recurrence have slowly rising PSA for years before developing clinically detectable metastatic disease, and some may never develop symptoms from the recurrence during their lifetime.
A long PSADT therefore can support less urgent management in appropriate patients, but it does not prove that recurrent cancer is absent.
Is 12 months an important PSA doubling-time threshold?
Yes, in some specific prostate-cancer settings.
For biochemical recurrence after radical prostatectomy, current EAU risk classification considers:
- PSADT greater than 12 months together with pathological ISUP Grade Group below 4 as part of the EAU low-risk recurrence category;
- PSADT 12 months or less or pathological Grade Group 4–5 as EAU high-risk biochemical recurrence.
This does not mean that 11.9 months represents aggressive cancer while 12.1 months represents harmless disease.
The threshold is a validated risk-stratification tool used with pathology and other clinical information.
| Clinical setting | PSADT reference | Meaning |
|---|---|---|
| BCR after prostatectomy | ≤12 months | Contributes to EAU high-risk biochemical-recurrence classification. |
| BCR after prostatectomy | >12 months | Can contribute to EAU low-risk classification when pathological Grade Group is also below 4. |
| Non-metastatic castration-resistant prostate cancer | <10 months | Defines a high-risk population in whom intensified androgen-receptor-targeted treatment improves metastasis-free and overall survival. |
| Other clinical settings | Varies | No single PSADT threshold should be transferred automatically between disease states. |
03. How Is PSA Doubling Time Interpreted After Prostate Cancer Treatment?
Why is PSA doubling time important after radical prostatectomy?
Radical prostatectomy removes almost all PSA-producing prostate tissue.
Current EAU guidance states that PSA is expected to become undetectable after prostatectomy, generally within approximately two months.
If PSA later becomes detectable and continues to rise, clinicians assess whether this represents biochemical recurrence and how biologically active that recurrence appears.
PSA doubling time helps with the second question.
A rapidly doubling PSA after surgery is associated with a greater likelihood of:
- distant metastatic recurrence;
- prostate-cancer-specific mortality;
- and clinically important progression.
But PSADT is not the only relevant variable.
Pathological Grade Group, tumor stage, surgical margins, absolute PSA, interval from surgery to recurrence and imaging findings also matter.
Does PSA doubling time define biochemical recurrence after surgery?
No.
PSADT describes the kinetics after PSA has begun rising.
It is not itself the definition of biochemical recurrence.
Current EAU guidance emphasizes that the PSA threshold and clinical meaning of recurrence depend on the primary treatment and that treatment decisions should consider more than one PSA number.
AUA salvage guidance similarly emphasizes confirming a rising PSA trend and treating appropriate post-prostatectomy recurrence while PSA remains low rather than waiting for a high absolute level simply to obtain a more dramatic doubling-time calculation.
How is PSA different after radiation therapy?
After radiation therapy, the prostate remains in place.
Normal prostate tissue therefore continues to produce some PSA.
PSA typically falls much more slowly after radiation than after prostatectomy, and reaching the post-treatment PSA nadir can take several years.
Current EAU guidance uses the Phoenix definition for biochemical failure after primary radiotherapy:
This is different from the post-prostatectomy setting.
A small detectable PSA after radiotherapy is therefore not automatically evidence of recurrence.
Is PSADT interpreted the same way after radiation?
No.
PSADT can still provide information about the pace of recurrent disease after radiotherapy, but current EAU biochemical-recurrence risk classification after radiation uses time to biochemical failure rather than PSADT as its principal kinetics variable.
The EAU low-risk category after radiotherapy requires:
- an interval to biochemical failure longer than 18 months;
- and biopsy ISUP Grade Group below 4.
An interval to biochemical failure of 18 months or less, or Grade Group 4–5, defines the EAU high-risk group.
This distinction is important because a PSADT threshold validated after prostatectomy should not simply be copied into post-radiation decision-making.
| After prostatectomy | After radiotherapy |
|---|---|
| Most prostate PSA-producing tissue has been removed. | The prostate remains and can continue producing PSA. |
| PSA is expected to become undetectable or very low. | PSA typically declines gradually to a nadir. |
| PSADT is part of EAU BCR risk classification. | EAU BCR risk classification primarily uses interval to biochemical failure plus Grade Group. |
| A rapidly rising low PSA may prompt early salvage evaluation. | A detectable PSA alone can be expected and must be interpreted relative to nadir and treatment course. |
04. How Does PSA Doubling Time Affect Follow-Up, Imaging and Treatment?
Does a shorter PSA doubling time mean imaging is needed?
A shorter PSADT increases concern for clinically meaningful progression, but imaging decisions are not made from doubling time alone.
After biochemical recurrence following radical prostatectomy, current EAU guidance recommends PSMA PET/CT when PSA is above approximately 0.2 ng/mL if the scan result will influence subsequent treatment decisions.
PSA kinetics can affect the likelihood of finding recurrent disease, but imaging yield also depends strongly on the absolute PSA concentration.
Does PSADT determine treatment by itself?
No.
Treatment decisions may incorporate:
- PSA doubling time;
- absolute PSA;
- pathological Grade Group;
- tumor stage;
- time since the original treatment;
- surgical margin status;
- PSMA PET or other imaging;
- previous radiotherapy or hormonal treatment;
- life expectancy;
- symptoms;
- and patient preferences.
PSADT is therefore a prognostic variable, not a treatment prescription.
Why is a PSA doubling time under 10 months important in non-metastatic castration-resistant disease?
This is a separate and more advanced disease setting.
In men with non-metastatic castration-resistant prostate cancer, a PSADT shorter than approximately 10 months identifies a population at high risk of developing metastases.
Current EAU guidance recommends treatment with androgen-receptor pathway inhibitors such as apalutamide, darolutamide or enzalutamide in appropriate patients with this high-risk pattern.
This 10-month threshold should not be applied to an untreated man having routine PSA screening.
Can PSA doubling time be used before prostate cancer has been diagnosed?
It can be calculated mathematically whenever PSA is rising, but it is generally not the preferred tool for deciding whether an undiagnosed man has prostate cancer.
For initial diagnostic evaluation, clinicians place greater emphasis on:
- the absolute PSA;
- confirmation of a newly elevated PSA;
- age and clinical risk;
- percent-free PSA or other biomarkers when appropriate;
- PSA density;
- prostate examination;
- and prostate MRI.
PSADT is most clinically established as a marker of disease behavior once prostate cancer is already known, particularly after treatment or in advanced disease.
What should happen when PSA is rising after treatment?
The next step depends on the original treatment and the clinical situation.
After prostatectomy, clinicians may confirm the rising trend, estimate PSADT, review pathology and consider early salvage treatment and PSMA PET/CT when appropriate.
After radiotherapy, PSA is interpreted relative to the post-treatment nadir and possible PSA bounce before recurrence is assumed.
A rapidly rising PSA generally warrants closer review than a very slowly rising PSA, but treatment should still be based on the full assessment.
PSA Doubling Time Examples
| PSA pattern | Time pattern | Approximate PSADT | What it demonstrates |
|---|---|---|---|
| 0.2 → 0.4 → 0.8 | Each value 6 months apart | 6 months | Rapid repeated doubling. |
| 0.5 → 1.0 | 12 months | 12 months | PSA doubled over one year. |
| 1.0 → 2.0 | 24 months | 24 months | Slower PSA doubling. |
| 1.0 → 1.1 → 1.0 | Serial measurements | No meaningful doubling | Generally stable PSA rather than exponential growth. |
| 4.0 → 3.0 → 2.5 | Serial measurements | Not a positive doubling pattern | PSA is declining. |
These examples explain the concept. Actual clinical PSADT should be calculated from appropriately selected serial measurements using a validated method.
PSA Doubling Time at a Glance
| Question | Practical answer |
|---|---|
| What is PSA doubling time? | The estimated time required for a rising PSA concentration to double. |
| What is the abbreviation? | PSADT or PSA-DT. |
| How is it expressed? | Usually in months or years. |
| Is PSADT the same as PSA velocity? | No. Velocity measures absolute annual change; doubling time measures exponential growth. |
| How is clinical PSADT calculated? | Usually from the slope of the natural logarithm of serial PSA values over time. |
| How many measurements are recommended? | EAU guidance recommends at least three PSA measurements. |
| Should tests be taken days apart? | Usually no. A minimum interval of about four weeks is preferred to reduce statistical noise when clinically appropriate. |
| What does a short PSADT mean? | PSA is increasing rapidly and progression risk is generally higher. |
| What does a long PSADT mean? | PSA is increasing more slowly and risk is generally lower than with a short PSADT. |
| Does short PSADT prove metastasis? | No. |
| Does long PSADT rule out recurrence? | No. |
| Is 12 months important after prostatectomy? | Yes. PSADT ≤12 months contributes to the EAU high-risk BCR category after radical prostatectomy. |
| Is PSADT under 10 months important? | Yes, particularly in non-metastatic castration-resistant prostate cancer, where it defines a high-risk disease group. |
| Does PSADT diagnose biochemical recurrence? | No. Recurrence definitions depend on the treatment received. |
| What happens to PSA after prostatectomy? | It is expected to become very low or undetectable because most PSA-producing tissue has been removed. |
| What happens after radiotherapy? | PSA usually falls gradually because the prostate remains in place. |
| What defines biochemical failure after radiotherapy? | The Phoenix definition uses a PSA rise of 2 ng/mL above the post-treatment nadir. |
| Can PSADT locate recurrence? | No. Imaging such as PSMA PET/CT is used for localization when appropriate. |
Summary
- PSA doubling time measures how long a rising PSA would take to double.
- It is generally reported in months or years.
- Shorter PSADT means PSA is increasing more rapidly.
- Longer PSADT means PSA is increasing more slowly.
- PSADT measures exponential PSA growth rather than simple absolute annual change.
- The standard mathematical approach uses ln(2) divided by the slope of ln(PSA) over time.
- Current EAU guidance recommends at least three PSA measurements for clinical PSADT calculation.
- A minimum interval of approximately four weeks between PSA samples is preferable when clinically appropriate.
- EAU guidance recommends using measurements from no more than roughly the preceding 12 months when the goal is to represent current disease activity.
- Different PSADT calculation methods can produce somewhat different results.
- PSA doubling time is not the same as tumor-volume doubling time.
- PSADT is most clinically useful in men with known prostate cancer rather than as a stand-alone initial screening test.
- After radical prostatectomy, PSA is expected to become very low or undetectable.
- A short PSADT after post-prostatectomy recurrence is associated with greater metastatic and mortality risk.
- Current EAU classification considers PSADT of 12 months or less a high-risk feature after biochemical recurrence following prostatectomy.
- After radiotherapy, the prostate remains in place and PSA declines more slowly.
- Biochemical failure after radiotherapy is commonly defined as PSA rising 2 ng/mL above the post-treatment nadir.
- EAU recurrence risk classification after radiotherapy uses interval to biochemical failure rather than applying the post-prostatectomy PSADT threshold directly.
- A PSADT shorter than 10 months identifies high-risk non-metastatic castration-resistant prostate cancer.
- PSADT does not tell clinicians where recurrent disease is located.
- PSMA PET/CT and other imaging may be used to localize recurrence when the result will influence treatment.
- A short PSADT does not automatically determine treatment.
- A long PSADT does not prove that recurrent prostate cancer is harmless.
- Absolute PSA, pathology, imaging, treatment history and other patient factors remain necessary for interpretation.
Educational disclaimer: This article provides general medical education about PSA doubling time. PSADT should not be used alone to diagnose recurrent prostate cancer, determine whether cancer has metastasized or choose treatment. Its meaning depends on the treatment previously received, absolute and serial PSA values, pathology, imaging, testosterone status, other cancer-risk features and the wider clinical situation.
Explore the PSA Pathway
For the broader PSA testing framework, return to PSA Testing and Prostate Screening.
For the difference between an annual PSA change and exponential PSA growth, see What Is PSA Velocity?.
For interpretation of PSA relative to prostate size, see What Is PSA Density?.
For the underlying laboratory biomarker, see What Is PSA?.
For benign reasons a PSA measurement can rise even when prostate cancer is not present, see What Causes a High PSA? and Can PSA Be High Without Prostate Cancer?.
The next guide explains how ejaculation can temporarily affect PSA testing and how timing before a blood test matters.
Evidence Sources
- European Association of Urology. Prostate Cancer Guidelines — PSA Velocity, PSA Doubling Time, Biochemical Recurrence and Treatment.
- European Association of Urology. Prostate Cancer Guidelines — PSA Monitoring After Radical Prostatectomy and Radiotherapy.
- American Urological Association / ASTRO / SUO. Salvage Therapy for Prostate Cancer Guideline — Biochemical Recurrence After Primary Treatment.
- Arlen PM, et al. Prostate Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling Time. Journal of Urology.
- Benecchi L, et al. Optimal Measure of PSA Kinetics to Identify Prostate Cancer — PSA-DT Calculation Using the Natural Logarithm of PSA.
